Access the full text.
Sign up today, get DeepDyve free for 14 days.
Fetal parvovirus B 19 infection and liver disease of antenatal onset in an infant with Ebstein ’ s anomaly
McOmish McOmish, Yap Yap, Jordan Jordan (1993)
Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reactionJ Clin Microbiol, 31
P. Mortimer, N. Luban, J. Kelleher, B. Cohen (1983)
TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATESThe Lancet, 322
P. Mortimer, R. Humphries, J. Moore, R. Purcell, N. Young (1983)
A human parvovirus-like virus inhibits haematopoietic colony formation in vitroNature, 302
(1987)
Pure red cell aplasia associated with human immunodeficiency virus infection : response to intravenous gammaglobulin ( abstract )
C. Kasper, J. Lusher (1993)
Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices CommitteeTransfusion, 33
G. Kurtzman, N. Frickhofen, J. Kimball, D. Jenkins, A. Nienhuis, N. Young (1989)
Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.The New England journal of medicine, 321 8
Brown Brown, Hibbs Hibbs, Gallinella Gallinella (1994)
Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen)N Engl J Med, 330
Human parvovirus B 19 infection in hemophiliacs first infused with two high - purity , virally attenuated factor VIII concentrates
(1996)
Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalisInternational Journal of Gynecology & Obstetrics, 54
A. Grosse-Bley, A. Eis-Hübinger, R. Kaiser, J. Oldenburg, H. Brackmann, T. Schwarz, K. Schneweis (1994)
Serological and Virological Markers of Human Parvovirus B19 Infection in Sera of HemophiliacsThrombosis and Haemostasis, 72
MMWR Morb Mortal Wkly Rep, 36
H. Rollag, G. Patou, J. Pattison, M. Degré, Stein Evensen, S. Frøland, A. Glomstein (1991)
Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools.Scandinavian journal of infectious diseases, 23 6
Hypoplastic anemia in a hemophiliac first infused with a solvent / detergent treated factor VIII concentrate : the role of human B 19 parvovirus ( letter )
Frickhofen Frickhofen, Abkowitz Abkowitz, Safford Safford (1990)
Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV‐1): a treatable cause of anemia in AIDSAnn Intern Med, 113
Persistent B19 parvovirus infection in patients infected with human immunovirus type I (HIV-I): a treatable cause of anemia in AIDS
W. Koch (1995)
A synthetic parvovirus B19 capsid protein can replace viral antigen in antibody-capture enzyme immunoassaysJournal of Virological Methods, 55
Division of Infectious Disease, Department of Pediatrics, Medical College of Virginia
Jordan Jordan (1996)
Identification of human parvovirus B19 infection in idiopathic non‐immune hydrops fetalisAm J Obstet Gynecol, 174
M. Williams, B. Cohen, A. Beddall, K. Pasi, P. Mortimer, F. Hill (1990)
Transmission of Human Parvovirus B19 by Coagulation Factor ConcentratesVox Sanguinis, 58
N. Luban (1994)
Human parvoviruses: implications for transfusion medicineTransfusion, 34
Srivastava Srivastava, Bruno Bruno, Briddell Briddell (1990)
Parvovirus B19‐induced perturbation of human megakaryocytopoiesis in vitroBlood, 76
Background: The long‐term consequences of parvovirus B19 infection in transfusion recipients are not known, and thus the value of B19 screening of blood donors remains unresolved. Hemophiliacs, at risk for B19 through their chronic exposure to clotting factor concentrates, have frequent, close medical follow‐up and thereby constitute an ideal group in which to study the hematologic sequelae of B19 infection. Study Design and Methods: An enzyme‐linked immunosorbent assay was used to detect B19 IgG and IgM and the polymerase chain reaction was used to detect B19 DNA in frozen, stored plasma samples, obtained between 1987 and 1994, from 136 subjects with hemophilia, including 71 who were human immunodeficiency virus (HIV)‐positive and 65 who were HIV‐ negative. Then the results of the tests were compared with clinical hematological data and blood product usage data. Results: B19 seroprevalence in the hemophilic cohort was 81.6 percent (111/136), including 74.6 percent (53/71) of HIV‐positive and 89.2 percent (58/65) of HIV‐negative hemophiliacs. It was not affected by age, type or severity of hemophilia, HIV status, CD4 number, or yearly blood product usage. Only 1 (0.7%) of the 136 samples was positive for B19 IgM and none was positive in polymerase chain reaction for B19 DNA. After adjusting for HIV status, there were no differences between B19‐ positive and B19‐negative hemophiliacs in hematologic values, CD4 counts, or blood product use. Conclusion: Although B19 IgG seroprevalence in this hemophilic cohort is high and indicative of past B19 infection, there is no detectable B19 viral activity or any associated long‐term clinical or hematologic sequelae.
Transfusion – Wiley
Published: Mar 1, 1996
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.